Business
Key oral care brand - clinical trial on COVID-19
Key oral care brand - clinical trial on COVID-19.
About this update from Venture Life Group Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 8936W\n Venture Life Group PLC\n 24 August 2020\n \n \n \n \n 24 August 2020\n \n \n \n \n \n \n \n \n VENTURE LIFE GROUP PLC\n \n \n (\"Venture Life\" \"VLG\" or the \"Group\")\n \n \n Venture Life's leading oral care brands participation in UK clinical trial on COVID-19 patients\n \n \n Venture Life (AIM: VLG), a leader in developing, manufacturing and commercialising products for the self-care market, announced on 15 May 2020 that it supported further research into the idea that using mouthwash could reduce the transmission of enveloped viruses such as COVID-19. Today the Company announces its involvement in a UK-led clinical trial on COVID-19 patients, in partnership with Cardiff University. This independent multi-centre clinical study, which is being led by Professor David Thomas at Cardiff University, will investigate the possibility that using over-the-counter mouthwashes could help to reduce the viral load and therefore the transmission of COVID-19 in the mouth. Venture Life is delighted to confirm that its leading mouthwash, Dentyl, will be involved in this UK clinical trial.\n \n \n \n \n \n A literature review of previous research led by Professor Valerie O'Donnell at Cardiff University and expert input from a group of virologists, microbiocide experts, lipid specialists and healthcare experts from the universities of Cardiff, Nottingham, Ottawa and Barcelona, published in May 2020, suggested the possibility that certain mouthwashes could be used to help reduce transmission of enveloped viruses such as SARS-CoV2, but that more research was needed to test this idea. The review concluded that Cethylpyridinium Chloride (CPC) may be effective in this respect. Venture Life's Dentyl mouthwash, which is currently sold in the UK and eleven other countries, contains CPC as its main active ingredient. \n \n \n \n \n \n Venture Life is delighted to be partnering with Cardiff University and its affiliates, in order to help facilitate this valuable research. The clinical study entitled 'The measurement of mouthwash anti-viral activity against COVID-19' (MOMA) will be commencing in August and is expected to last for 12 weeks. This is a multi-centre study and will recruit patients currently in hospital with COVID-19, commencing at Cardiff hospital. \n \n \n \n \n \n \n Pro...